Clovis Oncology, Inc. (CLVS) Raised to Strong-Buy at BidaskClub

Geronimo Vena
Agosto 13, 2017

A number of other brokerages also recently commented on CLVS. Credit Suisse Group set a $107.00 price target on Clovis Oncology and gave the company a buy rating in a research report on Tuesday, July 18th.

On June 20, 2017 the stock rating was rated "Buy" in a report from Janney Capital up from the previous "Neutral" rating. They set a "market perform" rating on the stock. J P Morgan Chase & Co raised Clovis Oncology from a "neutral" rating to an "overweight" rating and set a $72.00 price objective for the company in a research report on Wednesday, May 17th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $79.00 price objective on shares of Clovis Oncology in a research note on Tuesday, June 20th. Finally, Zacks Investment Research raised Clovis Oncology from a hold rating to a buy rating and set a $105.00 price target for the company in a research report on Wednesday, July 12th. Clovis Oncology now has an average rating of "Buy" and a consensus target price of $81.59.

The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! The company's 50-day moving average is $87.18 and its 200-day moving average is $67.07. The stock of Clovis Oncology Inc (NASDAQ:CLVS) earned "Sell" rating by Chardan Capital Markets on Friday, February 3.

There has been some selling insider activity on Clovis Oncology, Inc.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Wednesday, August 2nd. As of the latest earnings report the EPS was $-8.90 and is estimated to be $-7.51 for the current year with 48,879,000 shares now outstanding. The firm had revenue of $14.62 million during the quarter, compared to analyst estimates of $13.07 million.

Clovis Oncology, Inc., launched on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. They expect $0.10 earnings per share, down 23.08% or $0.03 from last year's $0.13 per share. On average, equities research analysts anticipate that Clovis Oncology, Inc. will post ($7.51) earnings per share for the current year. Atwood And Palmer holds 0% in Clovis Oncology Inc (NASDAQ:CLVS) or 100 shares. "(NASDAQ:CLVS)" was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another website, it was stolen and republished in violation of USA and worldwide trademark & copyright legislation. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/12/versant-venture-management-llc-has-9-54-million-stake-in-clovis-oncology-inc-nasdaqclvs.html.

More notable recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Gurufocus.com which released: "Adams Street Partners Llc Buys Box Inc, Clovis Oncology Inc, Zendesk Inc ..." on August 03, 2017, also Streetinsider.com with their article: "Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS) Enter Clinical ..." published on July 31, 2017, Prnewswire.com published: "Technical Snapshots for These Biotech Stocks - Exelixis, Celldex Therapeutics ..." on July 24, 2017. The stock was sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the transaction, the director now directly owns 2,185 shares of the company's stock, valued at approximately $171,762.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4,000 Costco Wholesale Corporation (NASDAQ:COST) shares with value of $667,799 were sold by Rose Timothy L. The insider McKay John D sold 3,000 shares worth $544,810. Following the transaction, the insider now directly owns 203,583 shares in the company, valued at $9,647,798.37. The disclosure for this sale can be found here. Insiders sold a total of 27,450 shares of company stock worth $2,052,665 over the last ninety days. Hanseatic Management Ser owns 19 shares. It turned negative, as 30 investors sold CLVS shares while 48 reduced holdings. First Mercantile Trust Co. bought a new position in shares of Clovis Oncology during the first quarter valued at approximately $115,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Clovis Oncology by 71.4% in the first quarter.

Company shares last traded at $69.59 which is significantly lower than the 50 day moving average which is $87.91 and just a bit higher than the 200 day moving average of $66.98. Oppenheimer Holdings, Inc. began coverage on shares of Clovis Oncology in a research note on Friday, June 23rd. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company's stock worth $84,788,000 after buying an additional 1,318,669 shares during the period. Pnc Services Gp Incorporated stated it has 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). The fund owned 7,680 shares of the biopharmaceutical company's stock at the end of the second quarter. Two Sigma Investments LP bought a new stake in shares of Clovis Oncology during the fourth quarter valued at about $953,000. Institutional investors own 90.67% of the company's stock.

Clovis Oncology, Inc.is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The Company's fragrance products include a range of men's and women's products. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE